Follow-On Biologics Guidance Delay Lauded By Senate Health Cmte. Staffer

FDA should not issue a guidance on follow-on biologics until after Congress has established a regulatory pathway, Senate Health Committee Counsel Steve Irizarry said at an American Conference Institute meeting in New York June 25

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet